21 results on '"Cona, M.S."'
Search Results
2. Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy
3. 114P Effects of chemotherapy on TREG lymphocytes in early breast cancer
4. EP17.06-01 COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study
5. 1665P Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
6. 390P SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
7. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]
8. 1616P Drop in early-stage colorectal cancer diagnoses after COVID-19: Preliminary report from the COVID-DELAY study
9. 1609P COVID-19 outbreak repercussions on breast cancer diagnoses and access to treatment: Preliminary data from the COVID-DELAY study
10. 1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study
11. 35P Lung cancer diagnosis and continuum of care: How did the COVID-19 outbreak impact? Data from an Italian multicenter study
12. 1640P Pegylated liposomal doxorubicin (PLD) as first line treatment in AIDS-related Kaposi’s sarcoma (AIDS-KS): A single institution retrospective study
13. 1570P The emotional impact of COVID-19 outbreak on cancer out-patients and their caregivers: Impressions from the heart of the Italian pandemic
14. Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
15. 111P - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
16. Druggable aberrations in solid tumors: an overview on ALK and ROS-1 status
17. Lume trial: searching for survival prognostic factors in malignant pleural mesothelioma
18. Disthyroidism during immune checkpoints inhibitors treatment: toxicity or something more?
19. R32 - Druggable aberrations in solid tumors: an overview on ALK and ROS-1 status
20. R06 - Disthyroidism during immune checkpoints inhibitors treatment: toxicity or something more?
21. H12 - Lume trial: searching for survival prognostic factors in malignant pleural mesothelioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.